Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.

The list price of Basaglar will be $316.85 for a pack of five pens, 15% below the list price of Lantus. The companies also hope to steal market share from Novo Nordisk, undercutting the long ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, ...

Novo Nordisk (NVO) closed the most recent trading day at $69.30, moving -1.23% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.97%.